| DB ID | MyCo_3759 |
| Title | Prognostic Impact of Bronchoalveolar Lavage Fluid Galactomannan and Aspergillus Culture Results on Survival in COVID-19 Intensive Care Unit Patients: a Post Hoc Analysis from the European Confederation of Medical Mycology (ECMM) COVID-19-Associated Pulmonary Aspergillosis Study |
| Year | 2022 |
| PMID | 35321555 |
| Fungal Diseases involved | Pulmonary aspergillosis |
| Associated Medical Condition | COVID-19 |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | For the eight centres with data collection on all consecutive ICU patients, institutional review board approval numbers are as follows: Medical University of Graz EC #32-296 ex 19/20; University of Genoa Liguria Region Ethics Committee registry number 163/2020; for the centres from Belgium the study was approved by the ethical board of the University Hospital Leuven (S64071); at the University of Cologne patients were included in the FUNGISCOPE® global registry, which was approved by the local ethics committee of the University of Cologne, Cologne, Germany (identifier 05-102); at the University of Manchester data acquisition was conducted as a retrospective audit, which does not require local ethics but was approved by the hospital's audit committee. All centres followed local ethical requirements. The study has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Bronchoalveolar lavage fluid (BALF) |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | GM |
| Biomarker Full Name | Galactomannan |
| Biomarker Type | Prognostic |
| Biomolecule | Protein |
| Geographical Location | None |
| Cohort | Of the 592 patients enrolled in the main study, 239 underwent both BALF GM and BALF Aspergillus culture testing. Overall, 218 patients were eventually included in the present post hoc analysis. |
| Cohort No. | 218 |
| Age Group | 57–73 |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Technique | Assay |
| Analysis Method | GM Assay |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | GM Assay |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
